JTC Employer Solutions Trustee’s Recursion Pharmaceuticals RXRX Stock Holding History

JTC Employer Solutions Trustee’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53K	Hold	14,317	–	–	﹤0.01%	241
2026 Q1	$44K	Hold	14,317	–	–	﹤0.01%	245
2025 Q4	$58K	Hold	14,317	–	–	﹤0.01%	241
2025 Q3	$70K	Buy	14,317 +11,925	+499%	+$62.6K	0.01%	228
2025 Q2	$12K	Hold	2,392	–	–	﹤0.01%	273
2025 Q1	$13K	Hold	2,392	–	–	﹤0.01%	283
2024 Q4	$16K	Hold	2,392	–	–	﹤0.01%	278
2024 Q3	$16K	Hold	2,392	–	–	﹤0.01%	287
2024 Q2	$18K	Buy	+2,392	New	+$20.9K	﹤0.01%	286

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JTC Employer Solutions Trustee's RXRX Position: Q2 2026 in Review

JTC Employer Solutions Trustee held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 14,317 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #241.

JTC Employer Solutions Trustee first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $70K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

JTC Employer Solutions Trustee held 14,317 shares of Recursion Pharmaceuticals worth $53K as of Q2 2026.
JTC Employer Solutions Trustee left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of JTC Employer Solutions Trustee's portfolio in Q2 2026, its #241 holding.
JTC Employer Solutions Trustee first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
JTC Employer Solutions Trustee's Recursion Pharmaceuticals position peaked at $70K in Q3 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on JTC Employer Solutions Trustee's 13F filing for Q2 2026, filed 31 Jul 2026.